Showing results (1821-1830 of 11,285) with videos related to
Sort By:
Pageof 1,129
European Journal of Pharmacology|July 31, 1985
Involvement of amygdaloid catecholaminergic mechanism in suppressive effects of desipramine and imipramine on duration of immobility in rats forced to swimH Araki, K Kawashima, Y Uchiyama, et al.Archives of Dermatological Research|August 1, 1997
The role of granzyme B-expressing CD8-positive T cells in apoptosis of keratinocytes in lichen planusM Shimizu, Y Higaki, M Higaki, et al.Japanese Circulation Journal|December 10, 1997
The delayed recovery of impaired endothelium-dependent vasodilatory response after hemodynamic improvement in dogs with congestive heart failureM Ueno, S Kawashima, K Ikeoka, et al.Toxicology Letters|March 5, 1998
Developmental toxicity evaluation of phthalic acid, one of the metabolites of phthalic acid esters, in ratsM Ema, E Miyawaki, A Harazono, et al.Neuroreport|March 21, 1998
A PET study of axis orientation discriminationM Taira, R Kawashima, K Inoue, et al.Life Sciences|May 19, 1998
Acetylcholine synthesis and muscarinic receptor subtype mRNA expression in T-lymphocytesK Kawashima, T Fujii, Y Watanabe, et al.The European Journal of Neuroscience|March 6, 2023
Cortical oscillations and interareal synchronization as a preparatory activity for postural responseKimiya Fujio, Hiroki Obata, Kenta Takeda, et al.Arthroscopy Techniques|March 7, 2023
Flexion Contracture in Knee Osteoarthritis Can Be Fully Eliminated by Hybrid Closed Wedge High Tibial Osteotomy Using a Reduction-Insertion-Compression HandleRyuichi Nakamura, Masaki Amemiya, Fumiyoshi Kawashima, et al.Journal of Helminthology|September 1, 1985
The cercarial emergence of Schistosoma japonicum from Oncomelania quadrasi under outdoor conditions in the PhilippinesK Kawashima, B L Blas, A T SantosThe Journal of Dermatological Treatment|February 13, 2023
Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trialKenji Kabashima, Takayo Matsumura, Yoshiteru Hayakawa, et al.Pageof 1,129